DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided.
대표청구항▼
1. An inhalable dry powder formulation comprising a human DNase I protein and particles of a physiologically acceptable pharmacologically-inert solid carrier, wherein said human DNase I protein is a plant expressed recombinant human DNase I protein comprising an N-terminal Glycine residue at positio
1. An inhalable dry powder formulation comprising a human DNase I protein and particles of a physiologically acceptable pharmacologically-inert solid carrier, wherein said human DNase I protein is a plant expressed recombinant human DNase I protein comprising an N-terminal Glycine residue at position 1 of said human DNase I protein. 2. The inhalable pharmaceutical composition of claim 1, wherein said human DNase I protein comprising an N-terminal Glycine residue at position 1 of said human DNase I protein comprises the amino acid sequence as set forth in SEQ ID NO: 6. 3. The inhalable dry powder formulation of claim 1, wherein said human DNase I protein comprises the amino acid sequence as set forth in SEQ ID NO:5. 4. The inhalable dry powder formulation of claim 1, wherein said human DNase I protein has at least one core xylose and at least one core α-(1,3) fucose. 5. The inhalable dry powder formulation of claim 1, wherein said human DNase I protein has reduced susceptibility to actin inhibition of endonuclease activity as compared with that of mammalian cell expressed human recombinant DNase I. 6. The inhalable dry powder of claim 1, wherein said carrier is selected from the group consisting of (a) at least one crystalline sugar selected from the group consisting of glucose, arabinose, maltose, saccharose, dextrose, and lactose; and (b) at least one polyalcohol selected from the group consisting of mannitol, maltitol, lactitol, and sorbitol. 7. The inhalable dry powder formulation of claim 1, wherein said carrier is in a form of finely divided particles having a mass median diameter (MMD) in the range of 0.5 to 10 microns. 8. The inhalable dry powder formulation of claim 1, wherein said carrier is in a form of coarse particles having a mass diameter of 50-500 microns. 9. The inhalable dry powder formulation of claim 1, wherein said carrier comprises a mixture of coarse particles having a mass diameter of 150 microns to 400 micron and finely divided particles having a MMD in the range of 0.5-10 microns. 10. The inhalable dry powder formulation of claim 1, further comprising, as an active ingredient, a magnesium salt. 11. The inhalable dry powder formulation of claim 1, further comprising, as an active ingredient, an agent for inhibiting formation of G actin and/or enhancing formation of F actin. 12. The inhalable dry powder formulation of claim 1, wherein said human DNase I is in association with diketopiperazine. 13. The inhalable dry powder formulation of claim 1, wherein said human DNase I protein is at least 90-95% pure human DNase I protein. 14. The inhalable dry powder formulation of claim 1, further comprising plant beta-acetylhexosaminidase enzyme protein. 15. The inhalable dry powder formulation of claim 14, wherein said plant beta-acetylhexosaminidase enzyme protein is inactivated beta-acetylhexosaminidase enzyme protein. 16. A method of reducing DNA in a pulmonary secretion or fluid of a subject in need thereof, the method comprising administering to the subject the inhalable dry powder formulation of claim 1, thereby reducing DNA in the pulmonary secretion or fluid of the subject. 17. A method of treating a pulmonary disease or condition associated with excess DNA in a pulmonary secretion in a subject in need thereof, the method comprising administering to the subject the inhalable pharmaceutical composition of claim 1, thereby treating the pulmonary disease or condition associated with excess DNA in the pulmonary secretion in the subject. 18. The method of claim 16, wherein said subject is suffering from a respiratory disease selected from the group consisting of acute or chronic bronchopulmonary disease, atelectasis due to tracheal or bronchial impaction, and complications of tracheostomy. 19. The method of claim 18, wherein said acute or chronic bronchopulmonary disease is selected from the group consisting of infectious pneumonia, bronchitis or tracheobronchitis, bronchiectasis, cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD), TB or fungal infections. 20. The method of claim 19, wherein an effective amount of said dry powder formulation is a plurality of doses, each dose comprising 1.0-3.0 mg DNase, said doses administered at least twice, 2-3 times, 2-4 times or 2-6 times daily.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (85)
Ruskewicz Stephen J., Aerosol extrusion mechanism.
Musa, Rossella; Ventura, Paolo; Chiesi, Paolo, Carrier mixed with additives having lubricant properties for preparing powdery pharmaceutical compositions for inhalation.
Morinaga Tsuto (Sagamihara JPX) Miura Kin-ichiro (Tokyo JPX) Shimotohno Kunitada (Tokyo JPX) Ikegami Masato (Funabashi JPX) Ichikawa Yataro (Tokorozawa JPX), Double-stranded DNA having sequences complementary to a single-stranded DNA and derived from a bean golden mosaic virus.
Casper, Robert A.; Leith, Frank A.; Gardner, David L.; Snow, John M.; Lyon, Zachary W.; Farrar, David S., Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament.
Lloyd Lester J. (Orinda CA) Lloyd Peter M. (Oakland CA) Rubsamen Reid M. (Berkley CA) Schuster Jeffrey A. (Berkley CA), Dynamic particle size control for aerosolized drug delivery.
Ambrosio Thomas J. ; Ashley Charles R. ; Bilanin Alan J. ; Huck Charles M. ; Kaufman Andrew E. ; Kenyon David J. ; Manthena Srinivas ; Sochon Henry R. ; Wilkinson Ken ; Yang Tsong-Toh, Inhaler for powdered medications.
Lloyd Lester J. (Orinda CA) Rubsamen Reid M. (Berkeley CA), Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values.
Rubsamen Reid M. (Berkeley CA) Lloyd Lester J. (Orinda CA) Johansson Eric T. (Dublin CA), Lockout device for controlled release of drug from patient-activated dispenser.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Villax Peter (Lisbon PTX) Peres Rui (Cascais PTX) Treneman William Richard (Cambs GB3) McDerment Iain Grierson (Herts GB3) Bunce Martin (London GB3), Medicament inhaler and method.
Oliver Martin J.,GBX ; Fatania Kanu M.,GBX ; Scott John S.,GBX ; Muller Helgert,DEX, Medicinal aerosol products containing formulations of ciclesonide and related steroids.
Smith Adrian E. ; Burr John D. ; Etter Jeffery W. ; Axford George S. ; Lyons Shirley W. ; Platz Robert M., Method and apparatus for dispersion of dry powder medicaments.
Lloyd Peter M. (Oakland CA) Ritson Carl (San Jose CA) Johansson Eric T. (Dublin CA) Rubsamen Reid M. (Berkeley CA), Method and apparatus for sensing flow in two directions and automatic calibration thereof.
Steiner Solomon S. (Mount Kisco NY) Rhodes Christopher A. (Stamford CT) Shen Gregory S. (Hartsdale NY) McCabe R. Tyler (Yorktown NY), Method for making self-assembling diketopiperazine drug delivery system.
Sanford John C. (Geneva NY) Wolf Edward D. (Ithaca NY) Allen Nelson K. (Newfield NY), Method for transporting substances into living cells and tissues and apparatus therefor.
Armer Thomas Alex ; Evans Bryce Burwick ; Mohsen Nahed Mohsen ; Pavkov Richard Matthew ; Sudhalkar Atul M., Methods and apparatus for delivering aerosolized medication.
Armer Thomas Alex ; Evans Bryce Burwick ; Mohsen Nahed Mohsen ; Pavkov Richard Matthew ; Sudhalkar Atul M., Methods and apparatus for delivering aerosolized medication.
Steiner Solomon S. ; Feldstein Robert ; Lian Huiling ; Rhodes Christopher A. ; Shen Gregory S., Microparticles for lung delivery comprising diketopiperazine.
Donson Jon (Davis CA) Dawson William O. (Winter Haven FL) Granthan George L. (Riverside CA) Turpen Thomas H. (Vacaville CA) Turpen Ann M. (Vacaville CA) Garger Stephen J. (Vacaville CA) Grill Laurenc, Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.